FDMT
NASDAQ Healthcare4D Molecular Therapeutics, Inc. - Common Stock
Biotechnology
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
�� 市场数据
| 价格 | $10.49 |
|---|---|
| 成交量 | 894,935 |
| 市值 | 535.53M |
| 贝塔系数 | 2.930 |
| RSI（14日） | 61.4 |
| 200日均线 | $8.39 |
| 50日均线 | $9.29 |
| 52周最高 | $12.34 |
| 52周最低 | $2.96 |
| Forward P/E | -2.72 |
| Price / Book | 1.20 |
🎯 投资策略评分
FDMT 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (98/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 FDMT in your text
粘贴任何文章、记录或帖子 — 工具将提取 FDMT 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.